344 related articles for article (PubMed ID: 24365863)
1. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*.
MacLaren R; Campbell J
Crit Care Med; 2014 Apr; 42(4):809-15. PubMed ID: 24365863
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Histamine
Hammond DA; Kathe N; Shah A; Martin BC
Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
[TBL] [Abstract][Full Text] [Related]
3. Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial.
Krag M; Perner A; Wetterslev J; Wise MP; Borthwick M; Bendel S; Pelosi P; Keus F; Guttormsen AB; Schefold JC; Møller MH;
Trials; 2016 Apr; 17(1):205. PubMed ID: 27093939
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
Barkun AN; Adam V; Martel M; Bardou M
Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
[TBL] [Abstract][Full Text] [Related]
5. Stress-related mucosal bleeding in critically ill oncology patients.
Bruno JJ; Canada TW; Wakefield CD; Nates JL
J Oncol Pharm Pract; 2009 Mar; 15(1):9-16. PubMed ID: 18753185
[TBL] [Abstract][Full Text] [Related]
6. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.
Kantorova I; Svoboda P; Scheer P; Doubek J; Rehorkova D; Bosakova H; Ochmann J
Hepatogastroenterology; 2004; 51(57):757-61. PubMed ID: 15143910
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
Lin PC; Chang CH; Hsu PI; Tseng PL; Huang YB
Crit Care Med; 2010 Apr; 38(4):1197-205. PubMed ID: 20173630
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis.
Alhazzani W; Alenezi F; Jaeschke RZ; Moayyedi P; Cook DJ
Crit Care Med; 2013 Mar; 41(3):693-705. PubMed ID: 23318494
[TBL] [Abstract][Full Text] [Related]
9. Stress Ulcer Prophylaxis.
Barletta JF; Bruno JJ; Buckley MS; Cook DJ
Crit Care Med; 2016 Jul; 44(7):1395-405. PubMed ID: 27163192
[TBL] [Abstract][Full Text] [Related]
10. [Bleeding and pneumonia in intensive care unit patients given proton pump inhibitor or histamine-2 receptor antagonist for prevention of stress ulcer: a Meta analysis].
Zhou JF; Wan XY; Huang W; Han LL
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Apr; 22(4):221-5. PubMed ID: 20398466
[TBL] [Abstract][Full Text] [Related]
11. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients.
Buckley MS; Park AS; Anderson CS; Barletta JF; Bikin DS; Gerkin RD; O'Malley CW; Wicks LM; Garcia-Orr R; Kane-Gill SL
Am J Med; 2015 Aug; 128(8):905-13. PubMed ID: 25820164
[TBL] [Abstract][Full Text] [Related]
12. Time to declare a moratorium on stress ulcer prophylaxis in critically ill.
Alaniz C; Hyzy RC
Crit Care Med; 2014 Sep; 42(9):e636-7. PubMed ID: 25126822
[No Abstract] [Full Text] [Related]
13. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
14. Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.
Alhazzani W; Guyatt G; Alshahrani M; Deane AM; Marshall JC; Hall R; Muscedere J; English SW; Lauzier F; Thabane L; Arabi YM; Karachi T; Rochwerg B; Finfer S; Daneman N; Alshamsi F; Zytaruk N; Heel-Ansdell D; Cook D;
Crit Care Med; 2017 Jul; 45(7):1121-1129. PubMed ID: 28459708
[TBL] [Abstract][Full Text] [Related]
15. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
16. Stress ulcer prophylaxis: it's that same old wine in a brand new bottle*.
Erstad BL
Crit Care Med; 2014 Apr; 42(4):979-80. PubMed ID: 24633095
[No Abstract] [Full Text] [Related]
17. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
[TBL] [Abstract][Full Text] [Related]
18. Histamine 2 receptor antagonists vs intravenous proton pump inhibitors in a pediatric intensive care unit: a comparison of gastric pH.
Tofil NM; Benner KW; Fuller MP; Winkler MK
J Crit Care; 2008 Sep; 23(3):416-21. PubMed ID: 18725049
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis.
Barkun AN; Bardou M; Pham CQ; Martel M
Am J Gastroenterol; 2012 Apr; 107(4):507-20; quiz 521. PubMed ID: 22290403
[TBL] [Abstract][Full Text] [Related]
20. A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit.
Preslaski CR; Mueller SW; Kiser TH; Fish DN; MacLaren R
J Clin Pharm Ther; 2014 Dec; 39(6):658-62. PubMed ID: 25243327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
